1. Signaling Pathways
  2. Apoptosis
  3. Ferroptosis

Ferroptosis

Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.

Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.

Ferroptosis Related Products (109):

Cat. No. Product Name Effect Purity
  • HY-12320
    Cycloheximide Inhibitor 99.86%
    Cycloheximide (Naramycin A) is an eukaryote protein synthesis inhibitor, with IC50s of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.
  • HY-17394
    Cisplatin Activator >99.0%
    Cisplatin is a antineoplastic chemotherapy drug which works by cross-linking with DNA and causing DNA damage in cancer cells.
  • HY-12041
    SP600125 Inhibitor 98.82%
    SP600125 is a cell-permeable, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively.
  • HY-15763
    Erastin Activator 99.42%
    Erastin is a ferroptosis inducer. Erastin binds and inhibits voltage-dependent anion channels (VDAC2/VDAC3).
  • HY-10201
    Sorafenib Activator 99.92%
    Sorafenib (Bay 43-9006) is a potent, orally active multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-106376B
    D,L-Buthionine-(S,R)-sulfoximine hydrochloride Activator
    D,L-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
  • HY-100003
    ML-210 Activator 98.64%
    ML-210,the most potent compound in the nitroisoxazole series, is a selective covalent inhibitor of glutathione peroxidase 4 (GPX4) by binding the selenocysteine residue. ML-210 has IC50s of 71 nM, 272 nM and 107nM for BJeLR (HRASV12), BJeH-LT (without HRASV12) and DRD cell lines, respectively.
  • HY-W020044
    DL-alpha-Tocopherol Inhibitor
    DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB.
  • HY-100579
    Ferrostatin-1 Inhibitor 99.72%
    Ferrostatin-1 is a potent inhibitor of ferroptosis with an EC50 of 60 nM.
  • HY-15760
    Necrostatin-1 Inhibitor 99.87%
    Necrostatin-1 (Nec-1) is a potent, selective and cell-permeable necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 acts by inhibiting RIP1 kinase (EC50=182 nM) in the necroptosis pathway. Necrostatin-1 is also a indoleamine-2,3-dioxygenase (IDO) inhibitor.
  • HY-100523
    ML385 Activator 99.55%
    ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC50 of 1.9 μM.
  • HY-B0215
    Acetylcysteine Inhibitor >98.0%
    Acetylcysteine is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor.
  • HY-B0988
    Deferoxamine mesylate Inhibitor >99.0%
    Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.
  • HY-10295
    SB 202190 Inhibitor 99.89%
    SB 202190 is a cell-permeable p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM.
  • HY-17386
    Rosiglitazone Inhibitor 99.21%
    Rosiglitazone (BRL 49653) is a selective PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively.
  • HY-100218A
    (1S,3R)-RSL3 Activator 99.87%
    (1S,3R)-RSL3 is an inhibitor of glutathione peroxidase 4 (GPX4), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. (1S,3R)-RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
  • HY-N0005
    Curcumin Inhibitor 99.66%
    Curcumin (Diferuloylmethane) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.
  • HY-50898
    Lapatinib Activator 99.83%
    Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
  • HY-13419
    U-73122 Inhibitor 98.17%
    U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50of 1-2.1 µM for PLC.
  • HY-13426
    Roxadustat Activator 99.91%
    Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.